Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
tirzepatide — the active ingredient in Zepbound and its counterpart Mounjaro for diabetes — is fully available again. "FDA has determined that the shortage of tirzepatide injection products ...
After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...
Now with Zepbound, the revolution continues ... It's important to understand OSA symptoms and know that treatments are available, including new options like Zepbound. We hope this will spark more ...
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.